Biopharma: Encorafenibbased Regimens Provide Improved PFS and OS in DifficulttoTreat BRAFMutant Colorectal Cancer Compared to Historical Benchmarks
BOULDER Colo. June 4 2016 PRNewswire &160;Array BioPharma Nasdaq ARRY announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAFmutant colorectal cancer ...
Read full article »
CEO
Biopharma is a Private company. Biopharma has an estimated revenue of <$1M and an estimate of less <10 employees.